Novel therapeutic targets for abdominal aortic aneurysm treatment: evidence from recent preclinical research

Area of Science:

• Vascular Biology
• Pharmacology
• Genomics

Background:

• Small abdominal aortic aneurysms (AAA) currently lack effective treatments, necessitating urgent development of drug therapies.
• AAA pathogenesis involves complex mechanisms including extracellular matrix remodeling, dysregulated lipid metabolism, inflammation, immune responses, microRNA/epigenetic changes, and pro-thrombotic pathways.

Purpose of the Study:

• To review recent evidence from mouse models and patient samples to identify novel drug targets for limiting AAA growth and rupture.
• To explore mechanisms implicated in AAA pathogenesis and assess their potential as therapeutic targets.

Main Methods:

• Review of recent research involving mouse models of AAA.
• Validation of findings using human patient samples.
• Analysis of mechanisms including extracellular matrix remodeling, lipid metabolism, inflammatory/immune mediators, microRNA/epigenetic dysregulation, and pro-thrombotic pathways.

Main Results:

• Several key pathways implicated in AAA pathogenesis were identified, including extracellular matrix remodeling, lipid metabolism, inflammation, immune responses, microRNA/epigenetic dysregulation, and pro-thrombotic pathways.
• These pathways represent potential targets for novel drug therapies to manage AAA growth and rupture.

Conclusions:

• Future research should prioritize developing more accurate animal models that mimic human AAA for reliable drug target testing.
• Enhancing therapeutic efficacy and safety may involve improving targeting specificity and minimizing systemic exposure through targeted delivery systems like nanoparticles or viral vectors.
• Integrated cross-species analysis of single-cell RNA-sequencing data can identify conserved therapeutic targets and improve the translational relevance of animal models for AAA research.